2. Academic Validation
  3. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

  • Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15.
Shawn R Lockhart 1,  Annette W Fothergill 2,  Naureen Iqbal 1,  Carol B Bolden 1,  Nina T Grossman 1,  Edward P Garvey 3,  Stephen R Brand 3,  William J Hoekstra 3,  Robert J Schotzinger 3,  Elizabeth Ottinger 4,  Thomas F Patterson 5,  Nathan P Wiederhold 6
Affiliations

Affiliations

  • 1 Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • 2 University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • 3 Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA.
  • 4 National Institutes of Health, Therapeutics for Rare and Neglected Diseases, Bethesda, Maryland, USA.
  • 5 University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA South Texas Veterans Health Care System, San Antonio, Texas, USA.
  • 6 University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA wiederholdn@uthscsa.edu.
PMID: 26787697 DOI: 10.1128/AAC.02770-15
Abstract

Thein vitroactivities of the novel fungal CYP51 Inhibitor VT-1129 were evaluated against a large panel ofCryptococcus neoformansandCryptococcus gattiiisolates. VT-1129 demonstrated potent activities against bothCryptococcusspecies as demonstrated by low MIC50and MIC90values. ForC. gattii, thein vitropotency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole againstC. neoformans, including isolates with reduced fluconazole susceptibility.

Figures
Products